Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Veritas In Silico Inc. ( (JP:130A) ) has provided an announcement.
Veritas In Silico reported first-quarter fiscal 2026 results showing business revenue of 17 million yen against operating expenses of 139 million yen, resulting in a net loss of 256 million yen, as it continues to invest heavily in its mRNA-targeting platform and pipeline. The platform business advanced through ongoing joint discovery projects, a new memorandum of understanding with Swiss firm SpiroChem, and contract talks with eight domestic and overseas partners, underscoring its push to expand collaborations.
The pipeline business remains on track, with preparations for animal studies in one in-house program and the generation of multiple candidates in another, targeting patent filings by 2026. The company also highlighted progress around a novel nucleic acid therapeutic for ALS, including a joint press conference with The Jikei University School of Medicine, and said commercialization plans for its Perfusio product are crystallizing as it begins PMDA consultations and partner selection toward a planned 2027 launch.
More about Veritas In Silico Inc.
Veritas In Silico Inc., listed on the TSE Growth Market, operates in the biotechnology and pharmaceutical sector, focusing on mRNA-targeted therapeutics. The company runs a dual business model of a platform business built around joint drug discovery research and a pipeline business developing in-house nucleic acid drug candidates, with a market focus on innovative treatments such as ALS therapies.
Average Trading Volume: 32,530
Technical Sentiment Signal: Sell
Current Market Cap: Yen3.01B
Find detailed analytics on 130A stock on TipRanks’ Stock Analysis page.